GlassScriptPhysician profile
Cecelia M Howard
NPI 1518378843
$3,838.17
in general payments reported to CMS, 2019-2025
21 companies · $1,440 in 2025
The $1,440 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $256 · 2022: $519 · 2023: $770 · 2024: $854 · 2025: $1,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,063.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,035.26 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $856.35 | 2021-2024 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $408.18 | 2021-2025 | Tremfya, Stelara, Simponi |
| Phathom Pharmaceuticals, INC. | $222.00 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $195.76 | 2025 | Sucraid |
| Madrigal Pharmaceuticals | $195.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $166.79 | 2023-2025 | |
| Lilly USA, LLC | $146.02 | 2024-2025 | Omvoh, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $130.88 | 2021-2024 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $100.13 | 2022-2025 | |
| Ardelyx, INC. | $98.92 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $90.95 | 2023-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $52.18 | 2024 | Dificid |
| Aimmune Therapeutics, INC. | $22.18 | 2025 | Zenpep |
| Evoke Pharma, INC. | $20.37 | 2023 | Gimoti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $18.26 | 2021 | |
| Ironwood Pharmaceuticals, INC | $18.06 | 2023 | Linzess |
| Ferring Pharmaceuticals INC. | $17.44 | 2024 | Rebyota |
| Redhill Biopharma INC. | $16.50 | 2024 | Talicia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.00 | 2023 | Cyltezo |
| Braintree Laboratories, INC. | $12.82 | 2023 | Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecelia Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.